ERK介导的炎性反应参与肾缺血再灌注损伤

目的研究小鼠肾缺血再灌注损伤的发病机制。方法建立小鼠肾缺血再灌注损伤模型。12只雄性C57BL／6随机分为2个组（n=6）,分别为假手术组（Sham）,肾缺血再灌注损伤模型组（IRI）。IRI组血管夹夹闭左肾动脉,置于32℃温箱后1h松开血管夹,去除右肾。Sham组操作同上,但不夹闭左肾动脉。再灌注24h后处死小鼠,收集血清和肾脏标本。测定血清肌酐（Cr）和血尿素氮（BUN）。PAS染色后显微镜下观察肾脏形态学变化,Western印迹分析ERK、p-ERK的表达,PCR检测MCP-1、IFN-γ。结果与假手术组（Sham）相比,IRI组血清肌酐、血尿素氮明显升高,病理检查可见肾脏内肾小管上皮细胞明显肿胀坏死、蛋白管型形成明显,还可观察到炎性细胞浸润明显增加。ERK、p-ERKWestern印迹结果PCR显示MCP-1、TNF-α也明显上调,但ERK表达不变。结论在肾缺血再灌注中,ERK激活介导的炎性后府可能参与了肾扣伤。     

Down-regulated miR-15a mediates the epithelial–mesenchymal transition in renal tubular epithelial cells promoted by high glucose

High glucose (HG) has been reported to be associated with renal dysfunction. And one potential mechanism underlining the dysfunction is the epithelial–mesenchymal transition (EMT) of renal tubular epithelial cells. Present study showed that EMT was induced in the HG-treated renal tubular epithelial cells by promoting the expression of mesenchymal phenotype molecules, such as α-SMA and collagen I, and down-regulating the expression of epithelial phenotype molecule E-cadherin. Moreover, we have identified the down-regulation of miR-15a which was accompanied with the HG-induced EMT. And the miR-15a overexpression inhibited the α-SMA, collagen I expression, and the promotion of E-cadherin expression by targeting and down-regulating AP4 which was also significantly promoted by the HG in the renal tubular epithelial cells. Thus, this study revealed that the weakening regulation on the AP4 expression by miR-15a might contribute to the HG-induced EMT in the renal tubular epithelial cells.     

Assessment of the potential iridology for diagnosing kidney disease using wavelet analysis and neural networks

Alternative or complementary medicine emphasizes therapies that are claimed to improve quality of life, prevent disease, and address conditions that conventional medicine has limited success in curing. There are many techniques which are prevalent in many countries and these can cause harm if not scientifically evaluated. The objective of this paper is to validate the use of iridology to diagnose kidney abnormalities. Two subject groups were evaluated: one was 168 subjects free from kidney disease and the other was 172 subjects with chronic renal failure. The procedure to acquire, process and classify the iris images was designed in such a way that avoids any dependency on the iridologists by using wavelet analysis and Adaptive Neuro-Fuzzy Inference System. The results show a correct classification for both subjects with kidney problems and normal subjects of 82% and 93%, respectively. The proposed technique conducted on a systemic disease with ocular manifestations showed encouraging results. However, it is necessary to perform extensive studies with diseases that do not have ocular manifestations according to conventional medicine in order to validate iridology as a valid scientific technique.     

全凭静脉麻醉期间右美托咪定对靶控输注丙泊酚用量及血流动力学的影响

目的：探讨右关托咪定（dexmedetomidine,DEX）对行全凭静脉麻醉患者靶控输注（target controlled infusion,TCI）丙泊酚用量及拔管期间血流动力学的影响。方法：选择拟于全麻下行经鼻蝶窦垂体瘤切除术的患者30例（ASA I～II级）,随机分为两组,每组15例。试验组（D组）给予DEX负荷剂量0．5μg·kg-1,注药时间15rain,继以0．3μg·kg-1·h-1持续输注至修补硬膜时;对照纽（N组）在相同时间给予等容量生理盐水。两组麻醉诱导方法相同,术中以脑电双频指数（bispectral index,BIS）为麻醉深度监测指标,根据BIS值调节丙泊酚血浆靶浓度维持麻醉。记录拔管期间收缩压（SBP）、舒张压（DBP）和心率（HR）,并计算心肌氧耗指数（RPP）;记录丙泊酚平均用量、用药前后BIS值、呼吸恢复时间、睁眼时间、拔管时间及术中不良反应。结果：①D组给予负荷剂量后,BIS值由（95±3）降至（77±11）,差异有统计学意义（P〈0．01）。②与N组相比,D组丙泊酚用量减少28％,差异有统计学意义（P〈0．01）。⑧拔管期间SBP、DBP和HR与入室时比较,D组无明显变化,N组HR显著升高（P〈0．05）;D组拔管期间SBP、DBP、HR和RPP明显低于N组（P〈0．05）;④两组患者呼吸恢复时间、睁眼时间及拔管时间差异均无统计学意义;⑤两组不良反应（心动过缓、高血压、低血压）的发生率无显著性差异。结论：术中持续静脉输注DEX可减少TCI丙泊酚用量,能使BIS值进一步降低,产生良好镇静效应;同时可有效减轻拔管期间循环变化,降低RPP,减少心肌耗氧量,提高拔管质量。     

后腹腔镜肾蒂淋巴管结扎术治疗乳糜尿(附46例报道)

目的:探讨后腹腔镜肾蒂淋巴管结扎术治疗乳糜尿的疗效,探讨微创治疗对乳糜尿的价值.方法:对2000年1月-2012年3月收治的92例乳糜尿患者随机分为实验组以及对照组,实验组患者采用后腹腔镜肾蒂淋巴管结扎术治进行治疗,对照组患者采用开放手术治疗,对两组患者手术时间、手术出血量、术后肠道恢复情况、拔管时间、术后下床活动时间、手术费用、住院肺炎以及住院天数、术后并发症的发生情况等进行比较.结果:实验组组手术时间为76.5±33.2 min、出血量为25.4±23.1mL、术后下床活动时间为39.8±5.6h、术后肠道恢复时间为33.5±5.4 h、手术住院天数为6.3± 2.4d、总住院天数为13.9±4.3 d、术后肺部感染发生例数为1例、术后切口感染发生例数为0例、术后体温大于38.5℃的例数为1例明显优于对照组的115.4± 23.2 min、187.3±56.7 mL、75.2±14.3 h、67.4± 15.4 h、12.3±4.5d、23.4± 7.3 d、5例、6例以及7例,实验组手术费用为7643±1453元高于对照组的3432±1043元,但实验组住院总费用为14854±2323元与对照组的14348±2134元无差异.结论:后腹腔镜肾蒂淋巴管结扎术对乳糜尿的治疗通过腹腔镜的放大使淋巴管结扎更完整同时其具有创伤小、术后住院时间短、术后无复发等特点.     

Wheat leaf lipids during heat stress: I. High day and night temperatures result in major lipid alterations

Understanding how wheat (Triticum aestivum L.) plants under high temperature (HT) regulate lipid composition is critical to developing climate‐resilient varieties. We measured 165 glycerolipids and sterol derivatives under optimum and high day and night temperatures in wheat leaves using electrospray ionization‐tandem mass spectrometry. Levels of polar lipid fatty acyl chain unsaturation were lower in both heat‐tolerant genotype Ventnor and susceptible genotype Karl 92 under HT, compared with optimum temperature. The lower unsaturation was predominantly because of lower levels of 18:3 acyl chains and higher levels of 18:1 and 16:0 acyl chains. Levels of 18:3‐containing triacylglycerols increased threefold/more under HT, consistent with their possible role in sequestering fatty acids during membrane lipid remodelling. Phospholipids containing odd‐numbered or oxidized acyl chains accumulated in leaves under HT. Sterol glycosides (SG) and 16:0‐acylated sterol glycosides (ASG) were higher under HT than optimum temperatures. Ventnor had lower amounts of phospholipids with oxidized acyl chains under HT and higher amounts of SG and 16:0‐ASG than Karl 92. Taken together, the data demonstrate that wheat leaf lipid composition is altered by HT, in which some lipids are particularly responsive to HT, and that two wheat genotypes, chosen for their differing physiological responses to HT, differ in lipid profile under HT.     

蝉棒束孢菌子实体对大鼠肾小管上皮细胞的影响

对蝉棒束孢菌子实体（0.75g/kg）重复灌胃SD雄性大鼠90d及恢复28d的早期肾损伤生物标记物肾损伤分子-1（KIM-1）和中性粒细胞明胶酶相关载脂蛋白（NGAL）进行测定,评估蝉棒束孢菌子实体对肾小管上皮细胞的影响;研究不同剂量蝉棒束孢菌子实体（0.25g/kg、0.5g/kg、1.0g/kg）对肾小管上皮细胞增殖和增生能力的影响。给药30、60、90d及恢复28d时,SD大鼠血清中KIM-1浓度与对照组相比均无显著差异（P>0.05）,给药30d、60d时,SD大鼠血清中NGAL浓度与对照组相比均无显著差异（P>0.05）,给药90d及恢复28d时,SD大鼠血清中NGAL浓度低于对照组（P<0.05）,且给药90d组与对照组相比有显著性差异（P<0.01）;免疫组化检测增殖细胞核抗原法（PCNA）及四甲基偶氮唑盐微量酶反应比色法（MTT）表明：与对照组相比,蝉棒束孢菌子实体能使肾小管上皮细胞增生能力增强,未导致肾小管上皮细胞凋亡。     

靶控输注依托咪脂在老年患者颌面外科手术中的应用效果

目的:研究靶控输注依托咪脂在老年患者颌面外科手术中的应用效果。方法:选择60例美国麻醉医师协会(ASA)分级I～II级行颌面外科手术的患者,并将其随机分为靶控输注丙泊酚组(P组,n=30)和靶控输注依托咪酯组(E组,n=30),记录麻醉诱导前、气管插管前、气管插管后5 min、手术开始时、停药时的有创收缩压、有创舒张压、心率,并记录手术时间、拔管时间、麻醉维持时依托咪酯和丙泊酚的靶控输注浓度。结果:P组气管插管前、气管插管后5 min、手术开始时、停药时血压均低于麻醉诱导前,且低于E组各对应时间点,差异均具有统计学意义(P0.05),P组气管插管前心率显著低于麻醉诱导前和E组(P0.05);E组气管插管前、气管插管后5 min和手术开始时血压均低于麻醉诱导前(P0.05),但各时间点心率无显著变化(P0.05)。P组靶控浓度为(1.95±0.54)μg/m L～(4.48±0.61)μg/mL,E组靶控浓度为(0.20±0.05)μg/mL～(0.51±0.05)μg/mL。两组药物拔管时间、术后恶心呕吐和躁动发生率差异无统计学意义(P0.05),但P组低血压发生率显著高于E组(P0.05)。结论:在颌面外科手术中,靶控输注依托咪脂,能有效减少麻醉诱导和维持中低血压发生,维持血流动力学稳定,对于老年患者而言,是一种比丙泊酚更为安全可靠的静脉麻醉药。     

骨化三醇联合腹膜透析疗法治疗慢性肾功能衰竭的临床疗效及对患者血清ProGRP、Cysc、Chemerin水平的影响

目的:探讨骨化三醇联合腹膜透析疗法治疗慢性肾功能衰竭的临床疗效及对患者血清Pro-Gastrin-Releasing Peptide (ProGRP)、CystatinC(Cysc)、Chemerin水平的影响。方法:选取我院2017年2月至2018年1月收治的98例慢性肾功能衰竭患者,按照随机数表法将其分为观察组(n=51)和对照组(n=47)。对照组采用腹膜透析疗法治疗,观察组采用骨化三醇联合腹膜透析疗法治疗。观察和比较两组治疗前后肾功能指标尿素氮(blood urea nitrogen,BUN)、血清肌酐(Serum creatinine Cr)、24小时尿蛋白(24 h urinary protein,24 h UP),生化指标白蛋白(albumin,Alb)、血红蛋白(hemoglobin,Hb)及红细胞(red blood cell,RBC),胃泌素释放肽前体(ProGRP)、血清胱抑素(Cys C)、趋化素(Chemerin)水平的变化,6个月、1年生存率及不良反应的发生情况。结果:治疗后,观察组BUN、SCr、24hUP水平均显著低于对照组[(13.95±3.06)mmol/L vs.(21.10±3.85)mmol/L,(260.12±40.32)μmol/L vs.(354.93±51.06)μmol/L,(1.75±0.45)g/24 h vs.(2.67±0.80)g/24 h](P0.05);Alb水平显著低于对照组[(27.85±3.58)g/L vs.(33.06±4.27)g/L](P0.05);Hb、RBC显著高于对照组[(91.72±13.46)g/L vs.(82.36±10.15)g/L,(379.47±92.08)×1012/L vs.(315.70±73.24)×1012/L](P0.05);ProGRP、Chemerin水平显著低于对照组[(49.23±4.72)pg/mL vs.(63.87±7.30)pg/mL,(37.02±6.15)μg/L vs.(30.63±4.81)μg/L](P0.05);Cysc水平显著高于对照组[(80.75±16.08)mL/min vs.(98.81±18.07)mL/min](P0.05);6个月、1年生存率均显著高于对照组[96.08%(49/51) vs. 91.49%(43/47),90.20%(46/51) vs. 74.47%(35/47)](P0.05);不良反应总发生率显著低于对照组[17.65%(9/51) vs. 44.68%(21/47)](P0.05)。结论:骨化三醇联合腹膜透析疗法治疗慢性肾功能衰竭的临床效果显著优于单用,其可有效减轻患者的临床症状,纠正电解质紊乱,改善肾功能和预后,可能与降低血清ProGRP、Chemerin水平及提高血清Cysc水平有关。     

高通量血液透析治疗慢性肾衰竭尿毒症的疗效及对尿毒症毒素、免疫球蛋白及肺功能指标的影响

目的:探讨高通量血液透析(HFHD)治疗慢性肾衰竭尿毒症的疗效及对尿毒症毒素、免疫球蛋白及肺功能指标的影响。方法:选取90例于2012年1月-2017年3月期间在喀什地区第一人民医院治疗的慢性肾衰竭尿毒症患者,依据随机数字表法将其分为对照组(n=45)和观察组(n=45),对照组给予血液透析滤过(HDF)治疗,观察组给予HFHD治疗,两组均透析治疗1个月。对比两组患者透析前后症状缓解情况及尿毒症毒素、免疫球蛋白及肺功能指标水平,记录两组相关并发症的发生情况。结果:透析治疗结束后观察组患者缓解率为91.11%(41/45),高于对照组的73.33%(33/45)(P0.05)。两组患者透析后血磷(P~-)、血钾(K~+)、甲状旁腺激素(PTH)、β2-微球蛋白(β2-MG)水平明显低于透析前,血钙(Ca~(2+))水平明显高于透析前(P0.05);观察组透析后K~+、Ca~(2+)、P~-等尿毒症毒素水平与对照组比较差异无统计学意义(P0.05),观察组透析后PTH、β2-MG水平明显低于对照组(P0.05)。透析后,两组患者的免疫球蛋白Ig M、Ig A、Ig G水平均较透析前上升,且观察组高于对照组(P0.05)。透析后,两组患者残气量(RV)均低于治疗前,最大肺活量(FVC)、肺活量(VC)、肺总量(TLC)均高于治疗前,且观察组RV低于对照组,FVC、VC、TLC均高于对照组(P0.05)。观察组并发症发生率为8.89%(4/45),低于对照组的24.44%(11/45)(P0.05)。结论:HFHD治疗慢性肾衰竭尿毒症能够安全有效地清除尿毒症毒素,缓解患者的临床症状,且能够提高患者的免疫功能和肺功能。